Novavax Inc. (NASDAQ:NVAX) Director Michael A. Mcmanus, Jr. bought 30,000 shares of the business’s stock in a transaction dated Wednesday, September 21st. The shares were bought at an average cost of $1.61 per share, with a total value of $48,300.00. Following the purchase, the director now directly owns 247,590 shares of the company’s stock, valued at $398,619.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Novavax Inc. (NASDAQ:NVAX) opened at 2.26 on Monday. The firm has a 50-day moving average of $6.38 and a 200 day moving average of $6.11. Novavax Inc. has a 12-month low of $1.16 and a 12-month high of $9.23. The firm’s market capitalization is $612.08 million.
Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $8.03 million. During the same quarter last year, the business posted ($0.08) earnings per share. The business’s revenue was down 82.1% compared to the same quarter last year. On average, equities analysts predict that Novavax Inc. will post ($1.09) EPS for the current year.
A number of analysts have recently commented on the stock. Chardan Capital reissued a “hold” rating and set a $5.75 target price on shares of Novavax in a research note on Sunday, August 14th. Citigroup Inc. boosted their target price on shares of Novavax from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. Guggenheim restated a “buy” rating and set a $25.00 price target on shares of Novavax in a research report on Monday, August 29th. Vetr upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price target on the stock in a research report on Tuesday, July 19th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $14.00 price target on shares of Novavax in a research report on Friday, September 9th. Seven investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.06.
Large investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Novavax by 40.1% in the first quarter. State Street Corp now owns 12,320,840 shares of the biopharmaceutical company’s stock worth $63,579,000 after buying an additional 3,527,714 shares during the period. Wellington Management Group LLP increased its stake in shares of Novavax by 43.4% in the first quarter. Wellington Management Group LLP now owns 12,711,938 shares of the biopharmaceutical company’s stock worth $65,593,000 after buying an additional 3,849,585 shares during the period. Bellevue Group AG purchased a new stake in shares of Novavax during the first quarter worth approximately $1,677,000. DIAM Co. Ltd. increased its stake in shares of Novavax by 2.6% in the second quarter. DIAM Co. Ltd. now owns 646,515 shares of the biopharmaceutical company’s stock worth $4,635,000 after buying an additional 16,660 shares during the period. Finally, Mckinley Capital Management LLC Delaware increased its stake in shares of Novavax by 99.5% in the second quarter. Mckinley Capital Management LLC Delaware now owns 980,955 shares of the biopharmaceutical company’s stock worth $7,132,000 after buying an additional 489,306 shares during the period. Institutional investors and hedge funds own 79.84% of the company’s stock.
Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.